Implementation of endometrial cancer molecular subtyping into a hybrid community-academic practice

Elizabeth O Ferreira; Alexandra M Schefter; Abby Brustad; Molly E Klein; Mahmoud A Khalifa; Boris Winterhoff; Andrew C Nelson

doi:10.1093/ajcp/aqae010

Implementation of endometrial cancer molecular subtyping into a hybrid community-academic practice

Am J Clin Pathol. 2024 Mar 2:aqae010. doi: 10.1093/ajcp/aqae010. Online ahead of print.

Authors

Elizabeth O Ferreira¹, Alexandra M Schefter², Abby Brustad³, Molly E Klein⁴, Mahmoud A Khalifa⁴, Boris Winterhoff², Andrew C Nelson⁴

Affiliations

¹ Department of Pathology, Max Rady College of Medicine, University of Manitoba, Winnipeg, Canada.
² Department of Obstetrics, Gynecology and Women's Health.
³ University of Minnesota Medical School, Minneapolis, MN, US.
⁴ Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, US.

PMID: 38430556
DOI: 10.1093/ajcp/aqae010

Abstract

Objectives: We sought to confirm utility of our institution's modified Proactive Molecular Risk Classifier for Endometrial Cancer protocol in our daily practice, which includes mismatch repair (MMR), p53, and L1 cell adhesion molecule (L1CAM) immunohistochemistry with in-house next-generation sequencing for POLE, TP53, and CTNNB1.

Methods: We conducted a retrospective review of all patients in our institution who underwent primary endometrial carcinoma resection from the year prior to protocol implementation (PRE; October 1, 2020, to September 30, 2021) through first year of implementation (POST; October 1, 2021, to September 30, 2022) to compare the distribution of molecular and traditional staging factors using GOG-249 criteria to assign clinical risk.

Results: In total, 136 of 260 PRE patients were classified as clinically low risk (LR), of whom 31 were MMR deficient. Of the 157 LR POST patients with endometrioid-type carcinoma, 45 were MMR deficient, 5 were POLE mutant, 5 were TP53 mutant, 56 were of no specific molecular profile (NSMP), and 46 did not receive full protocol testing. Of all 79 POST NSMP endometrioid-type cases, 18 were CTNNB1 mutated and 8 showed L1CAM expression.

Conclusions: Our protocol identified 22 (14%) of 157 LR tumors that harbored incipient intermediate- to high-risk molecular aberrations in TP53, CTNNB1, or L1CAM. Moving forward, results of ongoing trials assessing adjuvant therapy decisions based on molecular classification are necessary to confirm protocol utility and identify appropriate modifications.

Keywords: ProMisE Proactive Molecular Risk Classifier for Endometrial Cancer; biomarkers; endometrial cancer; molecular profiling; next-generation sequencing.